ATE542546T1 - Pde 4 inhibitoren zur behandlung der interstitiellen cystitis - Google Patents
Pde 4 inhibitoren zur behandlung der interstitiellen cystitisInfo
- Publication number
- ATE542546T1 ATE542546T1 AT04799810T AT04799810T ATE542546T1 AT E542546 T1 ATE542546 T1 AT E542546T1 AT 04799810 T AT04799810 T AT 04799810T AT 04799810 T AT04799810 T AT 04799810T AT E542546 T1 ATE542546 T1 AT E542546T1
- Authority
- AT
- Austria
- Prior art keywords
- pde
- inhibitors
- interstitial cystitis
- treatment
- pelvic pain
- Prior art date
Links
- 208000005615 Interstitial Cystitis Diseases 0.000 title abstract 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title 1
- 208000000450 Pelvic Pain Diseases 0.000 abstract 2
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 abstract 1
- 101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 abstract 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- CFBUZOUXXHZCFB-OYOVHJISSA-N chembl511115 Chemical compound COC1=CC=C([C@@]2(CC[C@H](CC2)C(O)=O)C#N)C=C1OC1CCCC1 CFBUZOUXXHZCFB-OYOVHJISSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 229950001653 cilomilast Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 201000007094 prostatitis Diseases 0.000 abstract 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 abstract 1
- 229960002586 roflumilast Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003390137 | 2003-11-20 | ||
| PCT/JP2004/017521 WO2005049087A1 (ja) | 2003-11-20 | 2004-11-18 | 慢性骨盤痛症候群治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE542546T1 true ATE542546T1 (de) | 2012-02-15 |
Family
ID=34616327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04799810T ATE542546T1 (de) | 2003-11-20 | 2004-11-18 | Pde 4 inhibitoren zur behandlung der interstitiellen cystitis |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20070167450A1 (de) |
| EP (1) | EP1685849B1 (de) |
| JP (1) | JPWO2005049087A1 (de) |
| AT (1) | ATE542546T1 (de) |
| CA (1) | CA2544322C (de) |
| ES (1) | ES2378374T3 (de) |
| PL (1) | PL1685849T3 (de) |
| PT (1) | PT1685849E (de) |
| WO (1) | WO2005049087A1 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0616633A2 (pt) * | 2005-09-29 | 2011-06-28 | Bayer Healthcare Ag | inibidores de pde e combinações dos mesmos para o tratamento de transtornos urológicos |
| EP2292089A1 (de) | 2008-01-11 | 2011-03-09 | Astellas Pharma Inc. | Modelltier mit hodenschmerzen oder beschwerden bei die hoden betreffenden handlungen und häufigem harndrang |
| EP2637649B1 (de) * | 2010-11-11 | 2014-12-24 | Akron Molecules AG | Verbindungen und verfahren zur behandlung von schmerz |
| EP2836240B1 (de) * | 2012-04-10 | 2019-03-13 | Georgia State University Research Foundation, Inc. | Zusammensetzungen und verfahren zur behandlung von mittelohrentzündung und anderen erkrankungen mit cyld-inhibitoren |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1046939C (zh) * | 1993-07-02 | 1999-12-01 | 比克·古尔顿·劳姆贝尔格化学公司 | 氟烷氧基取代的苯甲酰胺类及其制备方法和应用 |
| GB9404706D0 (en) | 1994-03-11 | 1994-04-27 | Smithkline Beecham Corp | Compounds |
| US5817670A (en) * | 1994-08-29 | 1998-10-06 | Yamanouchi Pharmaceutical Co., Ltd. | Naphthyridine derivatives and pharmaceutical compositions thereof |
| NZ322197A (en) | 1995-11-21 | 1999-02-25 | Yamanouchi Pharma Co Ltd | Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof |
| JPH11292877A (ja) | 1998-04-09 | 1999-10-26 | Yamanouchi Pharmaceut Co Ltd | １，４−ジ置換ピリドピラジン誘導体 |
| JPH11292878A (ja) | 1998-04-09 | 1999-10-26 | Yamanouchi Pharmaceut Co Ltd | イミダゾナフチリジン誘導体 |
| CA2331844A1 (en) | 1998-05-07 | 1999-11-11 | University Of Maryland, Baltimore | A method for diagnosing and treating chronic pelvic pain syndrome |
| TWI262919B (en) * | 1999-10-25 | 2006-10-01 | Yamanouchi Pharma Co Ltd | Naphthyridine derivative |
| GB0011802D0 (en) | 2000-05-16 | 2000-07-05 | Smithkline Beecham | Method for enhancing cognitive function |
| EP1161949A1 (de) * | 2000-06-09 | 2001-12-12 | Warner-Lambert Company | Verwendung von diazepinoindolen zur behandlung von chronisch obstruktiver lungenkrankheiten |
| CA2440141A1 (en) * | 2001-03-06 | 2002-09-12 | Cellegy Pharmaceuticals, Inc. | Compounds and methods for the treatment of urogenital disorders |
| RU2285002C2 (ru) * | 2001-06-15 | 2006-10-10 | Астеллас Фарма Инк. | Производное пиридина и фармацевтическая композиция на его основе |
| US7101847B2 (en) * | 2002-10-11 | 2006-09-05 | Milkhaus Laboratory, Inc. | Method of treating chronic pelvic pain syndrome by administration of chorionic gonadotropin |
-
2004
- 2004-11-18 AT AT04799810T patent/ATE542546T1/de active
- 2004-11-18 ES ES04799810T patent/ES2378374T3/es active Active
- 2004-11-18 CA CA2544322A patent/CA2544322C/en not_active Expired - Fee Related
- 2004-11-18 EP EP04799810A patent/EP1685849B1/de not_active Not-in-force
- 2004-11-18 US US10/580,417 patent/US20070167450A1/en not_active Abandoned
- 2004-11-18 JP JP2005515691A patent/JPWO2005049087A1/ja active Pending
- 2004-11-18 PT PT04799810T patent/PT1685849E/pt unknown
- 2004-11-18 PL PL04799810T patent/PL1685849T3/pl unknown
- 2004-11-18 WO PCT/JP2004/017521 patent/WO2005049087A1/ja not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2378374T3 (es) | 2012-04-11 |
| EP1685849A1 (de) | 2006-08-02 |
| CA2544322C (en) | 2012-05-08 |
| US20070167450A1 (en) | 2007-07-19 |
| PT1685849E (pt) | 2012-02-15 |
| CA2544322A1 (en) | 2005-06-02 |
| WO2005049087A1 (ja) | 2005-06-02 |
| PL1685849T3 (pl) | 2012-07-31 |
| EP1685849B1 (de) | 2012-01-25 |
| EP1685849A4 (de) | 2008-12-31 |
| JPWO2005049087A1 (ja) | 2007-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE122007000056I1 (de) | Beta-amino-tetrahydroimidazo (1,2-A)pyrazine und-tetrahydrotriazolo(4,3-A)pyrazine als dipeptidyl peptidase Inhibitoren zur Behandlung oder preventionvon Diabetes | |
| DE60133029D1 (de) | Mittel zur prävention oder behandlung von psoriasi | |
| NO20034056L (no) | Kombinasjoner av epotilonanaloger og kjemoterapeutiske midler for behandling av proliferative sykdommer | |
| CY1116992T1 (el) | Μεθοδος θεραπειας της σκληρυνσης κατα πλακας αναστελλοντας τη δραση της il-17 | |
| NO20035474D0 (no) | Prodrugs av GABA-analoger, sammensetninger og anvendelse derav | |
| EP1596854A4 (de) | Behandlung von erkrankungen im zusammenhang mit verringerter stickoxid-bioverfügbarkeit, einschliesslich erhöhte arginase | |
| ATE556713T1 (de) | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer | |
| DE60231804D1 (de) | Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomöostase störungen | |
| DK1212089T3 (da) | Synergistisk kombination af Roflumilast og Salmeterol | |
| MY145077A (en) | Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis | |
| ATE458485T1 (de) | Ubiquitin-ligase-hemmer und verwandte verfahren | |
| BRPI0607402A2 (pt) | uso de inibidores de pde7 para o tratamento de dor neuropática | |
| WO2004093803A3 (en) | Photochemotherapeutic compounds for use in treatment of pin1-associated states | |
| ATE380807T1 (de) | N-oxid von n-phenyl-2-pyrimidinaminderivaten | |
| MA28102A1 (fr) | Formulations pharmaceutiques, methodes et schemas d'administration pour le traitement et la prevention des syndromes coronariens aigus | |
| NO20062300L (no) | Fremgangsmater og reagenser for behandling av inflammatoriske forstyrelser | |
| EA200601884A1 (ru) | Бета-карболины, применяемые для лечения воспалительных заболеваний | |
| HRP20050572A2 (en) | Pde4 and pde3/4 inhibitors for use in the treatment of cachexia | |
| NO20062229L (no) | Middel og fremgangsmate for a behandle cancer omfattende strontium, aminosyre(r) og mineralagent(er) | |
| ATE542546T1 (de) | Pde 4 inhibitoren zur behandlung der interstitiellen cystitis | |
| ATE359808T1 (de) | Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma | |
| EA200301299A1 (ru) | Применение ингибиторов il-18 для лечения и предотвращения повреждений цнс | |
| TW200503672A (en) | 2-aminobenzoyl derivatives | |
| MXPA05010800A (es) | Acidos hidroxamicos utiles en el tratamiento de trastornos hiperproliferativos. | |
| ATE525071T1 (de) | Verbindngen zur hemmung der sap-bindung zur behandlung von osteoarthritis |